GlobalData on MSN14h
PhaseV and Alimentiv to support execution of adaptive clinical trials for GI
The partnership will integrate PhaseV's adaptive clinical trial technology with Alimentiv's comprehensive GI CRO services.
PhaseV and Alimentiv Partner on Machine Learning-Based Solution to Tackle Challenges in GI Clinical Trials
PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today it has entered a ...
FierceBiotech1d
GI-focused CRO Alimentiv ups trial tech with PhaseV’s adaptive machine learning software
Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...
Pharm Exec5d
Exploring the Advantages of Innovative Early Phase Trial Design
In early phase trials innovative designs offer potential for improvements in efficiency and decision-making. Determining the ...
clinicaltrialsarena1d
2021 was the leading year in rare disease trials
According to leading data and analytics company GlobalData’s Clinical Trials Database, over the past 20 years trial activity ...
appliedclinicaltrialsonline6d
Multiple Myeloma Research Foundation’s Horizon Clinical Trial Program
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...
appliedclinicaltrialsonline13d
Technology’s Role in Trial Design Optimization
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time ...
Outsourcing-pharma15d
Lindus Health: AI instrumental for predicting trial outcomes and shaping study design
We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025.
clinicaltrialsarena on MSN5d
FDA protocol deviation guidance could go further
The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.
PharmiWeb26d
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
LYT-200 is currently being evaluated in two ongoing Phase 1/2 adaptive design trials for the potential treatment of AML/MDS and head and neck cancers. About PureTech Health PureTech is a ...